Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bone Loss: full-pipeline trial registry
8 of 17 indexed Bone Loss trials are currently recruiting.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 8 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Bone Loss: 17 US clinical trials tracked, 8 recruiting.
Bone Loss is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.
Enrollment posture brief
Registry condition bone-loss
OPEN 8 | RECR 47% | LATE 4 | EARLY 4 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Disability Physical (47% recruiting · 17 trials)
Bone Loss lists 8 open slots (47% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bone Loss on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bone Loss recruits in line with its size-band peers.
8 of 17 indexed trials (47.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Bone Loss trials is spread across many organizations.
Northwestern University accounts for 2 of 17 trials (11.8%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Bone Loss trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
Bone Loss research is mostly interventional.
12 interventional and 5 observational studies make up this index (70.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
Insud Pharma
NCT05303636
Bone, Exercise, Alendronate, and Caloric Restriction
Wake Forest University Health Sciences
NCT05764733
An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects
AO Innovation Translation Center
NCT04112992
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
Wake Forest University Health Sciences
NCT04922333
Bone in CKD Alkali Response (BICARb Pilot Trial)
Albert Einstein College of Medicine
NCT05918029
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
Creighton University
NCT05701254
Lutein, Zeaxathin, and Fish Oil Supplementation
Texas A&M University
NCT06489873
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
University of Alabama at Birmingham
NCT04954664
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Indiana University
NCT04206436
TRE: Microbiome, Metabolic Health and Bone
Rutgers, The State University of New Jersey
NCT05548517
Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis
University of Alabama at Birmingham
NCT04964466
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Northwestern University
NCT02325414
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Massachusetts General Hospital
NCT00181584
Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency
United States Army Research Institute of Environmental Medicine
NCT01292395
Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass
Gundersen Lutheran Medical Foundation
NCT00975013
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
Northwestern University
NCT02025179
Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Thomas J. Schnitzer
NCT00826228
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 1 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Bone Loss records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bone Loss trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bone Loss page
17 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Bone Loss trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwestern University sponsors the most Bone Loss trials on record, review their full trial history before evaluating a specific study. See Northwestern University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bone Loss condition card totals 17 registered trials; most-linked intervention Placebo; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.